Contact this trialFirst, we need to learn more about you.
Microtubule Inhibitor
Eribulin + Pembrolizumab for Carcinosarcoma
Recruiting1 awardPhase 2
Toronto, Ontario
This trial tests eribulin and pembrolizumab in patients with recurring or worsening tubo-ovarian or uterine carcinosarcoma. Eribulin disrupts cancer cell structure, making them easier to attack, while pembrolizumab helps the immune system fight cancer by removing a protective shield on the cells. Eribulin has shown activity in various cancers, including ovarian and soft-tissue sarcomas.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service